Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments

Medicine and Dentistry

• In Vitro 100%
• Helminth 50%
• Metabolism 33%
• Oxamniquine 33%
• Excretion 16%
• Vascularity 16%
• Follow up 16%
• Pharmacodynamics 16%
• Pharmacokinetics 16%
• Buffer 16%
• Feeding 16%
• Effusion 16%
• In Silico 16%
• Bile 16%
• Drug 16%
• Chemotherapeutic Agent 16%
• Sulfotransferase 16%
• Oral Absorption 16%
• Therapeutic Procedure 16%
• Tissues 16%
• Tenidap 16%
• Examination 16%
• Inpatient 16%
• Liver 16%
• Plasma 16%
• Intestine 16%

Immunology and Microbiology

• Dose 50%
• Metabolism 33%
• Time 33%
• Pharmacokinetics 16%
• Blood Level 16%
• Knockout Mouse 16%
• Wild Type 16%
• Parasite 16%
• Schistosoma 16%
• Tissue Distribution 16%
• Pharmacodynamics 16%
• Excretion 16%
• Computer Model 16%
• Vascularization 16%
• Solubility 16%
• Bile 16%
• Permeability 16%
• Mouse 16%
• Intestine 16%
• Liver 16%
• Oral Absorption 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Oxamniquine 33%
• Buffer 16%
• Pharmacokinetics 16%
• Potassium Acetate 16%
• Effusion 16%
• Schistosoma 16%
• Mouse 16%
• Drug 16%
• Knockout Mouse 16%
• Parasite 16%
• Sulfotransferase 16%
• Tenidap 16%